oasis-4 semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) For people living with healthy weight Tamaño:40 mg

oasis-4 semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) For people living with healthy weight Tamaño:40 mg

For people living with obesity, access to care should be simple. NovoCare® Pharmacy offers a more affordable self-pay option, and the convenience of home delivery to make medicines easier to access. Discover

Verify with a reference chart

healthy weight

Tamaño:40 mg

Whether you’re just starting out or adjusting your routine, remember: progress doesn’t have to be perfect to be effective